# Everolimus trIal for Advanced prememopausaL Breast Cancer Patients

> **NCT02313051** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Goserelin
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT02313051
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2016-12
- **Final completion:** 2017-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02313051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02313051, "Everolimus trIal for Advanced prememopausaL Breast Cancer Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02313051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*